Company Description
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024.
Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2015 |
| IPO Date | May 24, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 366 |
| CEO | Sanj Patel |
Contact Details
Address: 105 Piccadilly, 2nd Floor London, W1J 7NJ United Kingdom | |
| Phone | 44 78 1431 9100 |
| Website | kiniksa.com |
Stock Details
| Ticker Symbol | KNSA |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001730430 |
| CUSIP Number | G5269C101 |
| ISIN Number | GB00BRXB0C07 |
| Employer ID | 98-1795578 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanj K. Patel | Chief Executive Officer and Chairman of the Board |
| Mark A. Ragosa C.F.A. | Executive Vice President and Chief Financial Officer |
| Ross Michael Moat | Executive Vice President, Chief Operating Officer and Principal Operating Officer |
| Dr. John F. Paolini FACC, M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Eben Tessari | Executive Vice President and Chief Strategy Officer |
| Michael R. Megna CPA | Senior Vice President and Chief Accounting Officer |
| Mei Jang | Senior Vice President and Chief Technical Officer |
| Jonathan Kirshenbaum | Investor Relations Officer |
| Douglas Barry | Senior Vice President, Chief Legal Officer and Secretary |
| Martina Struck Ph.D. | Senior Vice President and Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | 8-K | Current Report |
| Apr 16, 2026 | ARS | Filing |
| Apr 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2026 | 144 | Filing |
| Apr 9, 2026 | 144 | Filing |
| Apr 6, 2026 | 144 | Filing |
| Apr 6, 2026 | 144 | Filing |
| Apr 6, 2026 | 144 | Filing |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |